var data={"title":"Physostigmine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Physostigmine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6775?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=physostigmine-drug-information\" class=\"drug drug_general\">see &quot;Physostigmine: Drug information&quot;</a> and <a href=\"topic.htm?path=physostigmine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Physostigmine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061061\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Anticholinergic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Cholinergic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Cholinergic Agent, Ophthalmic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061056\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=physostigmine-drug-information\" class=\"drug drug_general\">see &quot;Physostigmine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note</b>: For IV, slow administration (&le;0.5 mg/minute for pediatric patients; &le;1 mg/minute for adults) is required to prevent bradycardia, respiratory distress, and seizures. In one retrospective chart review of adult patients with likely anticholinergic toxicity (n=45), 69% of patients only required a single dose of physostigmine; in addition, even in patients who required multiple doses of physostigmine, further dosing beyond 6.5 hours (after the initial dose) was generally unnecessary (Rosenbaum 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Reversal of toxic anticholinergic effects:</b> <b>Note:</b> Reserve for life-threatening situations only: Infants, Children, and Adolescents: IM, IV: Initial: 0.02 mg/kg; may repeat every 5 to 10 minutes until response occurs; maximum total dose: 2 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Reversal of toxic anticholinergic effects: </b>IM, IV: Initial: 0.5 to 2 mg; may repeat every 10 to 30 minutes until response occurs. Subsequent doses may be required to manage life-threatening anticholinergic effects (Krenzelok 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209674\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as salicylate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (2 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209658\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061065\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: May administer as undiluted solution</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Infuse undiluted solution slowly; maximum rate: Pediatric patients: 0.5 mg/minute; adults: 1 mg/minute. Too rapid administration can cause bradycardia and hypersalivation leading to respiratory distress and seizures. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132658\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent; use appropriate precautions for handling and disposal (EPA, P-listed).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209690\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061064\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Reversal of toxic, anticholinergic effects caused by clinical or toxic dosages of drugs (FDA approved in pediatric patients [age not specified] and adults).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Note:</b> Physostigmine should only be used to reverse toxic, life-threatening delirium caused by pure anticholinergic agents (ie, atropine, diphenhydramine, dimenhydrinate, <i>Atropa belladonna</i> [deadly nightshade], or jimson weed [<i>Datura</i> spp]). Consultation with a clinical toxicologist or poison control center is recommended in patients who require physostigmine administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209722\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Physostigmine may be confused with Prostigmin, pyridostigmine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209719\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Asystole, bradycardia, palpitations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Hallucination, nervousness, restlessness, seizure, twitching</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, frequent bowel movements, nausea, salivation, stomach pain, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urinary frequency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Lacrimation, miosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, dyspnea, pulmonary edema, respiratory distress, respiratory paralysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209681\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Gastrointestinal or genitourinary obstruction; asthma; gangrene; diabetes; cardiovascular disease; any vagotonic state; coadministration of choline esters and depolarizing neuromuscular-blocking agents (eg, succinylcholine) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209662\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Arrhythmias: Patient must have a normal QRS interval, as measured by ECG, in order to receive; use caution in poisoning with agents known to prolong intraventricular conduction (Howland, 2011). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cholinergic effects: Discontinue if symptoms of excessive cholinergic activity occur (eg, salivation, urinary incontinence, defecation, vomiting); overdosage may result in cholinergic crisis, which must be distinguished from myasthenic crisis. If excessive diaphoresis or nausea occurs, reduce subsequent doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity/overdose reactions: Due to the possibility of hypersensitivity or overdose/cholinergic crisis, atropine should be readily available. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sodium metabisulfite: Products may contain sodium metabisulfite which may cause allergic reactions in some individuals. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; IV administration: Administer no faster than 1 mg/minute in adults or 0.5 mg/minute in children to prevent bradycardia, respiratory distress, and seizures from too rapid administration. Although the use of continuous infusions of physostigmine have been described in the literature (Eyer, 2008; Hail, 2013), experts do not recommend the routine use of continuous infusions. It is preferable to titrate physostigmine to patient needs through the use of intermittent administration; intermittent administration will minimize the risk of cholinergic toxicity, which can be associated with considerable morbidity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tricyclic antidepressant (TCA) poisoning: Asystole and seizures have been reported when physostigmine was administered to TCA poisoned patients. Physostigmine is not recommended in patients with known or suspected TCA intoxication. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299877\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209667\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12703&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Amifampridine. Amifampridine side effects may also be increased. Amifampridine may enhance the therapeutic effect of Acetylcholinesterase Inhibitors. Acetylcholinesterase inhibitor side effects may also be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: Acetylcholinesterase Inhibitors may diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benoxinate: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Benoxinate. Specifically, the effects of benoxinate may be prolonged. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers. <b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: Acetylcholinesterase Inhibitors may increase the serum concentration of Succinylcholine.  Management: Consider alternatives to this combination due to a risk of prolonged neuromuscular blockade.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13823806\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey, 2003). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061060\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate, respiratory rate, ECG</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209661\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Physostigmine is a carbamate which inhibits the enzyme acetylcholinesterase and prolongs the central and peripheral effects of acetylcholine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209680\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Within 3 to 8 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: 45 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: IM: Readily absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely distributed throughout the body; crosses blood-brain barrier readily and reverses both central and peripheral anticholinergic effects</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Via hydrolysis by cholinesterases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 1 to 2 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323686\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Physostigmine Salicylate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (2 mL): $44.52</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038767\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anticholium (AT, DE);</li>\n      <li>Fisostigmina Salicilato (IT);</li>\n      <li>Fisostin (IT);</li>\n      <li>Physostigmine Salicylate (AU);</li>\n      <li>Physostigminum Salicylicum (PL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/physostigmine-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/physostigmine-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/physostigmine-pediatric-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/physostigmine-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eyer F, Jetzinger E, Pfab R, et al, &ldquo;Withdrawal from High-Dose Tranylcypromine,&rdquo; <i>Clin Toxicol (Phila)</i>, 2008, 46(3):261-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/physostigmine-pediatric-drug-information/abstract-text/18344110/pubmed\" target=\"_blank\" id=\"18344110\">18344110</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hail SL, Obafemi A, and Kleinschmidt KC, &ldquo;Successful Management of Olanzapine-Induced Anticholinergic Agitation and Delirium With a Continuous Intravenous Infusion of Physostigmine in a Pediatric Patient,&rdquo; <i>Clin Toxicol (Phila)</i>, 2013, 51(3):162-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/physostigmine-pediatric-drug-information/abstract-text/23473460/pubmed\" target=\"_blank\" id=\"23473460\">23473460</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Healthcare Environmental Resource Center (HERC). Pharmaceuticals&mdash;Hazardous Waste. &lt;web-link url=&quot;http://www.hercenter.org/hazmat/pharma.cfm#listed&quot; window=&quot;new&quot;&gt;http://www.hercenter.org/hazmat/pharma.cfm#listed&lt;/web-link&gt;. Published 2015. Accessed October 23, 2016.&lt;/reference&gt;&lt;reference&gt;Amphotericin B [prescribing information]. Big Flats, NY: X-Gen Pharmaceuticals; April 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howland M. Antidotes in depth: physostigmine salicylate. <i>Goldfrank's Toxicologic Emergencies</i>. 9th ed. Nelson LS, Hoffman RS, Lewin NA, et al, eds. New York, NY: McGraw-Hill; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krenzelok EP. Aspects of Datura poisoning and treatment. <i>Clin Toxicol (Phila)</i>. 2010;48(2):104-110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/physostigmine-pediatric-drug-information/abstract-text/20229618/pubmed\" target=\"_blank\" id=\"20229618\">20229618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Physostigmine injection [prescribing information]. Lake Forest, IL: Akorn, Inc; November 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenbaum C, Bird SB. Timing and frequency of physostigmine redosing for antimuscarinic toxicity. <i>J Med Toxicol</i>. 2010;6(4):386-392.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/physostigmine-pediatric-drug-information/abstract-text/20405266/pubmed\" target=\"_blank\" id=\"20405266\">20405266</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12703 Version 86.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1061061\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1061056\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F209674\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F209658\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1061065\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132658\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F209690\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1061064\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F209722\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F209719\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F209681\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F209662\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299877\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F209667\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13823806\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1061060\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F209661\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F209680\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323686\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038767\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12703|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=physostigmine-drug-information\" class=\"drug drug_general\">Physostigmine: Drug information</a></li><li><a href=\"topic.htm?path=physostigmine-patient-drug-information\" class=\"drug drug_patient\">Physostigmine: Patient drug information</a></li></ul></div></div>","javascript":null}